Abstract

P-glycoprotein is an energy-dependent drug efflux pump with broad specificity for hydrophobic antitumor agents such as vinblastine, doxorubicin, and taxol. We have previously shown that [3H]azidopine and [125I] iodoaryl azidoprazosin, which are photoaffinity probes for the alpha 1-subunit of the L-type calcium channel and alpha 1-adrenergic receptor, respectively, specifically interact with P-glycoprotein, partially reverse multidrug resistance, and bind to a 6-kDa common domain in the 140-kDa P-glycoprotein molecule (Greenberger, L., Yang, C.-P. H., Gindin, E., and Horwitz, S. B. (1990) J. Biol. Chem. 265, 4394-4401). An immunological approach was used to identify the position of photoaffinity drug-binding domains in P-glycoprotein. Analysis was done with a series of site-specific rabbit polyclonal antibodies to peptides that mimic domains in the mouse mdr1b gene product. The antibodies were made against amino acid residues 269-284, 356-373, 665-682, 740-750, 907-924, and 1203-1222. Upon trypsin digestion, cleavage products of 95 and 55 kDa were obtained, which after further digestion migrated at 60 and 40 kDa, respectively. The 40-kDa fragment was recognized by the antibodies to residues 1203-1222 and 919-1276, while the 55-kDa fragment was recognized by these antibodies plus antibodies to residues 740-750 and 907-924. In contrast, the 95- and 60-kDa trypsin fragments were recognized only by the antibody to residues 269-284. The 55- and 40-kDa fragments, as well as the 95- and 60-kDa fragments, were major photolabeled species after digestion of P-glycoprotein. The previously identified 6-kDa photo-labeled P-glycoprotein fragment was within the 40-kDa trypsin fragment. These data suggest that there are two photoaffinity drug-binding domains in P-glycoprotein encoded by mouse mdr1b. The C-terminal site most likely resides within or in close proximity to putative transmembrane domains 11-12.

Highlights

  • P-glycoprotein is an energy-dependent drug efflux ance to multiple antitumor drugs of diverse activities and pump with broad specificfiotyr hydrophobic antitumor structuressuch as doxorubicin, vincristine, and, insomecases, agents suchas vinblastine, doxorubicin, and taxol

  • Vinblastinecauses profound inhibition of photoaffinity labeling, doxorubicin is less inhibitory, and colchicine is as inhibitory, or less inhibitory, than doxorubicin (see Greenberger et al (1990)).Kinetic analysis suggeststhat P-glycoprotein substrates competitively inhibit the interaction of chemotherapeutic drugs with Pglycoprotein (Horio et al, 1988; NaitoandTsuruo, 1989)

  • The domain in theC-terminal half contains only the last two putative transmembrane domains (TM 11 and 12). This binding domain is ina homologous region compared with a binding domain of a verapamil analog (LU 49888) found in the a1subunit of the L-type calcium channel (Streissnig et al, 1990) and may help explain how verapamil can interact with both P-glycoprotein and the calcium channel

Read more

Summary

Little is known about the molecular mechanisms governing

Among the 500,000 deaths per year due to cancer in the the transport of chemotherapeutic drugs by P-glycoprotein. Vinblastinecauses profound inhibition of photoaffinity labeling, doxorubicin is less inhibitory, and colchicine is as inhibitory, or less inhibitory, than doxorubicin (see Greenberger et al (1990)).Kinetic analysis suggeststhat P-glycoprotein substrates competitively inhibit the interaction of chemotherapeutic drugs with Pglycoprotein (Horio et al, 1988; NaitoandTsuruo, 1989). These data suggestthat reversal agents andchemotherapeutic drugs share common binding domains in P-glycoprotein. This binding domain is ina homologous region compared with a binding domain of a verapamil analog (LU 49888) found in the a1subunit of the L-type calcium channel (Streissnig et al, 1990) and may help explain how verapamil can interact with both P-glycoprotein and the calcium channel

MATERIALS ANDMETHODS
RESULTS
Percent homology withb
DISCUSSION

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.